Mercer Global Advisors Inc. ADV Has $108,000 Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Mercer Global Advisors Inc. ADV lessened its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 93.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,603 shares of the biotechnology company’s stock after selling 219,620 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Ironwood Pharmaceuticals were worth $108,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Old West Investment Management LLC boosted its position in Ironwood Pharmaceuticals by 1.4% in the fourth quarter. Old West Investment Management LLC now owns 56,921 shares of the biotechnology company’s stock valued at $651,000 after buying an additional 761 shares in the last quarter. Texas Permanent School Fund Corp boosted its position in Ironwood Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 120,245 shares of the biotechnology company’s stock valued at $1,047,000 after buying an additional 1,557 shares during the last quarter. CWM LLC increased its stake in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 2,345 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of Ironwood Pharmaceuticals by 3.5% in the 2nd quarter. Louisiana State Employees Retirement System now owns 70,400 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 2,400 shares during the last quarter. Finally, SummerHaven Investment Management LLC grew its position in shares of Ironwood Pharmaceuticals by 3.6% during the 2nd quarter. SummerHaven Investment Management LLC now owns 72,030 shares of the biotechnology company’s stock worth $470,000 after buying an additional 2,491 shares during the period.

Wall Street Analysts Forecast Growth

IRWD has been the topic of a number of recent research reports. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Wells Fargo & Company reduced their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $12.00 to $4.00 in a research report on Thursday, August 8th. Finally, Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.17.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the transaction, the insider now directly owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 12.90% of the stock is owned by corporate insiders.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD opened at $4.02 on Wednesday. Ironwood Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $15.70. The stock has a market cap of $629.25 million, a PE ratio of -0.59 and a beta of 0.49. The firm has a 50-day moving average of $5.02 and a 200-day moving average of $6.40.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.